Pacira BioSciences (PCRX) Net Cash Flow Growth (3y) (2013 - 2026)
Pacira BioSciences (PCRX) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 32.03% |
| 3 | Zoetis | 32.60 Bn | 30.66 Bn | 1.62 Bn | 28.99% |
| 4 | Takeda Pharmaceutical | 27.53 Bn | 23.47 Bn | 4.39 Bn | 37.89% |
| 5 | United Therapeutics | 23.06 Bn | 20.91 Bn | 648.10 Mn | -49.94% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.32 Bn | 18.52 Bn | 1.16 Bn | 37.74% |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | -41.05% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -62.71% |
| 10 | Pacira BioSciences | 1.08 Bn | 873.48 Mn | 140.96 Mn | 40.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40.74% |
| Dec 31, 2025 | 60.72% |
| Sep 30, 2025 | -129.64% |
| Jun 30, 2025 | 29.25% |
| Mar 31, 2025 | 26.39% |
| Dec 31, 2024 | -59.14% |
| Sep 30, 2024 | -26.80% |
| Jun 30, 2024 | 17.26% |
| Mar 31, 2024 | 43.01% |
| Dec 31, 2023 | 60.60% |
| Sep 30, 2023 | -35.88% |
| Jun 30, 2023 | 28.85% |
| Mar 31, 2023 | -42.63% |
| Dec 31, 2022 | 8.55% |
| Sep 30, 2022 | -35.68% |
| Jun 30, 2022 | 12.32% |
| Mar 31, 2022 | -85.17% |
| Dec 31, 2021 | 87.47% |
| Sep 30, 2021 | -37.19% |
| Jun 30, 2021 | -19.64% |